{"id":20961,"date":"2026-04-07T12:18:57","date_gmt":"2026-04-07T15:18:57","guid":{"rendered":"https:\/\/ptbr.idor.org\/?post_type=ensaio_clinico&#038;p=20961"},"modified":"2026-04-24T14:32:38","modified_gmt":"2026-04-24T17:32:38","slug":"destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/","title":{"rendered":"DESTINY-Lung06 &#8211; CPNPC localmente avan\u00e7ado ou metast\u00e1tico &#8211; superexpress\u00e3o HER2 e PD-L1<50%"},"content":{"rendered":"<p>Trastuzumabe Deruxtecana combinado com Pembrolizumabe versus quimioterapia \u00e0 base de platina combinada com Pembrolizumabe como terapia de 1\u00aalinha.<\/p>\n<p><span data-olk-copy-source=\"MessageBody\">ClinicalTrials.gov: NCT06899126<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trastuzumabe Deruxtecana combinado com Pembrolizumabe versus quimioterapia \u00e0 base de platina combinada com Pembrolizumabe como terapia de 1\u00aalinha. ClinicalTrials.gov: NCT06899126<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-20961","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DESTINY-Lung06 - CPNPC localmente avan\u00e7ado ou metast\u00e1tico - superexpress\u00e3o HER2 e PD-L1<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DESTINY-Lung06 - CPNPC localmente avan\u00e7ado ou metast\u00e1tico - superexpress\u00e3o HER2 e PD-L1\" \/>\n<meta property=\"og:description\" content=\"Trastuzumabe Deruxtecana combinado com Pembrolizumabe versus quimioterapia \u00e0 base de platina combinada com Pembrolizumabe como terapia de 1\u00aalinha. ClinicalTrials.gov: NCT06899126\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-24T17:32:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\\\/\",\"name\":\"DESTINY-Lung06 - CPNPC localmente avan\u00e7ado ou metast\u00e1tico - superexpress\u00e3o HER2 e PD-L1\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2026-04-07T15:18:57+00:00\",\"dateModified\":\"2026-04-24T17:32:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"DESTINY-Lung06 &#8211; CPNPC localmente avan\u00e7ado ou metast\u00e1tico &#8211; superexpress\u00e3o HER2 e PD-L1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DESTINY-Lung06 - CPNPC localmente avan\u00e7ado ou metast\u00e1tico - superexpress\u00e3o HER2 e PD-L1","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/","og_locale":"pt_BR","og_type":"article","og_title":"DESTINY-Lung06 - CPNPC localmente avan\u00e7ado ou metast\u00e1tico - superexpress\u00e3o HER2 e PD-L1","og_description":"Trastuzumabe Deruxtecana combinado com Pembrolizumabe versus quimioterapia \u00e0 base de platina combinada com Pembrolizumabe como terapia de 1\u00aalinha. ClinicalTrials.gov: NCT06899126","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","article_modified_time":"2026-04-24T17:32:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/","name":"DESTINY-Lung06 - CPNPC localmente avan\u00e7ado ou metast\u00e1tico - superexpress\u00e3o HER2 e PD-L1","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2026-04-07T15:18:57+00:00","dateModified":"2026-04-24T17:32:38+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/destiny-lung06-cpnpc-localmente-avancado-ou-metastatico-superexpressao-her2-e-pd-l1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"DESTINY-Lung06 &#8211; CPNPC localmente avan\u00e7ado ou metast\u00e1tico &#8211; superexpress\u00e3o HER2 e PD-L1"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/20961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=20961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}